• Mashup Score: 0

    Receiving an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks lowered the rate of percent predicted FVC decline in progressive pulmonary fibrosis, according to a European Respiratory Society International Congress presentation.“Lysophosphatidic A and its receptor, LPA1, are involved in wound healing and have been implicated now in the pathogenesis of fibrotic diseases overall

    Tweet Tweets with this article
    • ICYMI 🚨: Treatment with an oral lysophosphatidic acid receptor 1 antagonist resulted in smaller decreases in percent predicted #FVC at 26 weeks vs. placebo in progressive #pulmonary #fibrosis. https://t.co/gYImYAUD69

  • Mashup Score: 0

    Patients with COVID-19-related acute respiratory distress syndrome undergoing transplantation had comparable, high survival rates to patients with COVID-19-related pulmonary fibrosis, according to results published in JAMA Surgery.Further, survival rates from these patients did not differ from those of patients who underwent lung transplantation for a non-COVID-19-related reason, according to

    Tweet Tweets with this article
    • ICYMI: Survival rates following lung #transplantation did not differ between those with #COVID-19 related #ARDS or pulmonary #fibrosis. https://t.co/VKPNGaneRa